1 	|BT| (NP (NP (NP (JJ Antagonistic) (NN effect) (NN selenium) (NN lipid) (NN peroxide)) (NN growth) (NN control) (JJ early) (JJ hepatocellular) (NN carcinoma))) |ET| |BS|45:G07.700.320.249 104:C04.557.470.200.025.255 934:D01.248.497.158.685.750.637 935:D01.268.185.850|ES| 19:1 75:1 102:1 289:1 303:1 304:1 1128:1 2401:1 3196:1 3283:1 3284:1

1 	|BT| (NP (NP (NP (JJ Anticancer) (NN effect) (NN wogonin) (NN estrogen) (JJ receptor-positive)) (: -) (NP (JJ negative) (JJ human) (NN breast) (NN cancer) (NN cell) (NN line) (NN vitro) (JJ nude) (NN mouse) (NN xenograft)))) |ET| |BS|55:B01.050.150.900.649.801.400.112.400.400 88:B01.050.150.900.649.865.635.505.500.550.500 92:E04.936.764 93:A01.941.875 94:A11.251.210 936:D12.776.826.750.350|ES| 18:1 19:1 23:1 36:1 52:1 75:1 94:1 216:1 264:1 265:1 266:1 2444:1 2446:1 3168:1 3285:1 3286:1

1 	|BT| (S (NP (JJ Antisense) (NP (JJ E1AF-transfected) (NN MKN45) (JJ gastric) (NN cancer) (NN cell))) (VP (VBD expressed) (NP (VBN reduced) (NN level) (NN matrilysin)) (NP (DT le) (NP (JJ invasive) (NN vitro) (JJ mock-transfected) (NN MKN45) (NN cell))))) |ET| |BS|41:A11 937:D08.811.277.656.300.480.525.700.250|ES| 6:1 18:1 19:1 86:1 94:1 144:1 216:1 249:1 452:1 489:1 2850:1 3287:1 3288:1 3289:1 3290:1

1 	|BT| (S (NP (NN Apoptosis) (JJ signal-regulating) (NN kinase) (CD 1)) (VP (VBZ inhibits) (NP (NP (NN hepatocarcinogenesis)) (VP (VBG controlling) (NP (JJ tumor-suppressing) (NN function) (JJ stress-activated) (JJ mitogen-activated) (NN protein) (NN kinase)))))) |ET| |BS|8:C04 122:C14.280.383 478:D08.811.913.696.620.682.700.567 938:D08.811.913.696.620.682.700.559.500|ES| 4:1 19:1 33:1 98:1 470:1 615:1 900:1 2220:1 3291:1 3292:1 3293:1 3294:1 3295:1

1 	|BT| (NP (NP (NN Aspirin) (NN use) (NN survival) (NN diagnosis) (JJ colorectal) (NN cancer))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 96:I03.784 263:E01 670:D02.455.426.559.389.657.410.595.176|ES| 17:1 18:1 19:1 274:1 1037:1 1659:1 2449:1

1 	|BT| (NP (NP (NN BACKGROUND) (: :)) (NP (NP (NNP Drug) (NN combination) (NN therapy)) (VP (VBG using) (NP (NP (NN cisplatin) (JJ natural) (NN product)) (JJ common) (NN practice) (NN treatment) (JJ human) (NN lung) (NN cancer))))) |ET| |BS|52:E02 55:B01.050.150.900.649.801.400.112.400.400 498:D01.210.375 793:D20.215 939:E02.319.310|ES| 18:1 19:1 36:1 104:1 130:1 328:1 350:1 530:1 546:1 655:1 675:1 1046:1 1761:1 2333:1 2345:1 3296:1

1 	|BT| (S (NP (NN BACKGROUND) (: :)) (NP (NP (JJ Epidermal) (NN growth) (NN factor) (JJ receptor-tyrosine) (NN kinase) (NN inhibitor)) (PRN (-LRB- -LRB-) (NP (NN EGFR-TKIs)) (-RRB- -RRB-))) (VP (VBD approved) (NP (NP (NN patient)) (JJ recurrent) (NP (NP (JJ non-small) (NN cell) (NN lung) (NN cancer)) (PRN (-LRB- -LRB-) (NP (NN NSCLC)) (-RRB- -RRB-)))))) |ET| |BS|50:M01.643 64:D08.811.913.696.620.682.725.400.009.300 110:C04.588.894.797.520.109.220.249 496:C23.550.291.937 634:D12.125.072.050.875|ES| 10:1 14:1 18:1 19:1 94:1 102:1 104:1 120:1 185:1 328:1 329:1 380:1 470:1 694:1 1046:1 1753:1 2340:1 2343:1 3297:1 3298:1

1 	|BT| (S (NP (NP (NP (NN Balb/c) (NN mouse) (VBN treated) (NN azoxymethane)) (PRN (-LRB- -LRB-) (NP (NN AOM)) (-RRB- -RRB-))) (NN dextran) (NN sulfate) (NN sodium)) (VP (VBP induce) (NP (NN colon) (NN cancer)))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 52:E02 131:D09.698.365.272.300 132:D02.172.080 940:B01.050.050.199.520.520.338|ES| 10:1 14:1 18:1 19:1 52:1 113:1 243:1 406:1 407:1 1099:1 1993:1 1994:1 3299:1 3300:1

1 	|BT| (S (NP (NP (NP (NN Beta-catenin/T-cell) (NN factor)) (PRN (-LRB- -LRB-) (NP (NN Tcf)) (-RRB- -RRB-))) (NN signaling)) (NP (RB constitutively) (JJ active) (NN majority) (JJ human) (JJ colorectal) (NN cancer)) (, ,) (VP (VBG accompanying) (NP (NN change) (NN Bcl-2) (NN expression)))) |ET| |BS|4:C04.588.274.476.411.307 23:D12.776.091.249 54:G05.360.340.024.340.375.500.791.150 55:B01.050.150.900.649.801.400.112.400.400 68:A11.118.637.555.567.569 69:G02.111.087.800|ES| 2:1 10:1 14:1 17:1 18:1 19:1 36:1 115:1 158:1 185:1 193:1 194:1 195:1 196:1 197:1 198:1 199:1 200:1

1 	|BT| (S (NP (NN Beta-ionone)) (VP (VP (VBZ inhibits) (NP (JJ colonic) (JJ aberrant) (NN crypt) (NN focus) (NN formation) (NN rat))) (, ,) (VP (VBZ suppresses) (NP (NN cell) (NN growth))) (, ,) (VP (VBZ induces) (NP (NN retinoid) (NN X) (NN receptor-alpha) (JJ human) (NN colon) (NN cancer) (NN cell))))) |ET| |BS|20:G03.495 41:A11 45:G07.700.320.249 46:A03.556.124.526.356 55:B01.050.150.900.649.801.400.112.400.400 122:C14.280.383 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 824:C04.834.020 941:D12.776.826.701.500.500|ES| 2:1 18:1 19:1 36:1 43:1 94:1 102:1 113:1 214:1 615:1 677:1 686:1 849:1 929:1 1431:1 1725:1 1889:1 2454:1 2573:1 2913:1

1 	|BT| (FRAG (NP (NNP Boswellia) (NNP serrata) (NN resin) (NN extract)) (VBZ alleviates) (NP (NP (NN azoxymethane)) (PRN (-LRB- -LRB-) (NP (NN AOM)) (-RRB- -RRB-))) (: /) (NP (NP (NN dextran) (NN sodium) (NN sulfate)) (PRN (-LRB- -LRB-) (NP (NN DSS)) (-RRB- -RRB-))) (: -) (NP (VBN induced) (NN colon) (NN tumorigenesis))) |ET| |BS|32:C04.697.098.500 33:C04.697.098 46:A03.556.124.526.356 131:D09.698.365.272.300 132:D02.172.080 942:D05.750.078.840.490|ES| 10:1 14:1 19:1 78:1 113:1 406:1 407:1 409:1 1993:1 1994:1 2496:1 3301:1 3302:1 3303:1 3304:1 3305:1 3306:1

1 	|BT| (S (NP (JJ Branched-chain) (NN amino) (NN acid) (-LRB- -LRB-) (NN BCAA) (-RRB- -RRB-)) (, ,) (VP (VB improve) (NP (NP (NN protein) (NN malnutrition) (NN patient) (NN liver) (NN cirrhosis)) (, ,) (S (VP (VB reduce) (NP (NN risk) (JJ hepatocellular) (NN carcinoma) (NN patient) (NN obesity))))))) |ET| |BS|50:M01.643 61:E05.318.740.600.800 104:C04.557.470.200.025.255 357:C06.552.630 564:C18.654.726.500 639:D12.125.070 943:C18.654.521.719.500|ES| 2:1 4:1 10:1 14:1 19:1 120:1 171:1 303:1 304:1 836:1 1199:1 1275:1 2010:1 2189:1 2360:1 2361:1 2465:1 2466:1 3307:1

1 	|BT| (S (NP (NP (NN Breast) (NN cancer)) (VP (VBG expressing) (NP (VBN activated) (NN HER2/neu) (JJ sensitive) (FW gefitinib) (FW vitro) (FW vivo)))) (VP (VBZ acquires) (NP (NN resistance) (JJ novel) (NN point) (NN mutation) (NN HER2/neu)))) |ET| |BS|63:G05.360.340.024.340.375.500.791.295.305 259:D12.776.395.240.150.500 438:G05.365.590.675|ES| 18:1 19:1 34:1 163:1 216:1 378:1 810:1 891:1 901:1 1094:1 2121:1 3308:1 3309:1 3310:1 3311:1

1 	|BT| (NP (NP (NP (NN BTG3) (NN tumor) (NN suppressor) (NN gene) (NN promoter) (NN demethylation)) (, ,) (NP (NN histone) (NN modification) (NN cell) (NN cycle) (NN arrest)) (NP (NN genistein) (JJ renal) (NN cancer)))) |ET| |BS|206:G05.360.340.024.340.375.249 399:D12.776.660.470 773:G04.299.134.109 944:D03.383.663.283.266.450.400.375|ES| 2:1 7:1 9:1 18:1 19:1 83:1 94:1 503:1 601:1 602:1 700:1 922:1 2374:1 3312:1 3313:1 3314:1

1 	|BT| (S (NP (NN Caveolin-1)) (VP (VBZ enhances) (NP (JJ resveratrol-mediated) (NN cytotoxicity) (NN transport) (JJ hepatocellular) (NN carcinoma) (NN model)))) |ET| |BS|104:C04.557.470.200.025.255 945:D12.644.360.024.264 946:D27.888.569.213 947:G03.495.166|ES| 19:1 72:1 303:1 304:1 1356:1 3315:1 3316:1 3317:1 3318:1

1 	|BT| (S (NP (JJ Cellular) (JJ FLICE-inhibitory) (NN protein) (NN down-regulation)) (VP (VBZ contributes) (NP (JJ celecoxib-induced) (NN apoptosis) (JJ human) (NN lung) (NN cancer) (NN cell)))) |ET| |BS|39:G04.299.139.160 41:A11 55:B01.050.150.900.649.801.400.112.400.400 85:G02.111.087.225 684:D02.065.884.247 948:D12.644.360.024.296.024|ES| 4:1 18:1 19:1 36:1 89:1 94:1 257:1 328:1 845:1 3319:1 3320:1 3321:1

1 	|BT| (NP (NP (NN Characterization) (JJ nuclear) (JJ receptor-mediated) (JJ murine) (NN hepatocarcinogenesis) (NN herbicide) (NN pronamide) (JJ human) (NN relevance))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 55:B01.050.150.900.649.801.400.112.400.400 949:D27.720.031.700.366 950:D12.776.826|ES| 19:1 36:1 627:1 900:1 1064:1 1256:1 3123:1 3322:1 3323:1 3324:1

1 	|BT| (S (NP (NNP Chitinase) (JJ 3-like) (CD 1)) (VP (VBZ promotes) (NP (NN macrophage) (NN recruitment) (NN angiogenesis) (JJ colorectal) (NN cancer)))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 658:A11.329.372 951:D08.811.277.450.207|ES| 17:1 18:1 19:1 98:1 298:1 2402:1 2502:1 3325:1 3326:1 3327:1

1 	|BT| (S (NP (NNP Chlorophyllin)) (VP (VP (VBN shown) (ADVP (RB significantly)) (VP (VB reduce) (S (NP (JJ genotoxic) (NN AFB) (NNS biomarkers)) (ADJP (JJ human))))) (, ,) (ADVP (RB therefore)) (VP (VBP hold) (NP (NP (NN promise) (JJ practical) (NN mean)) (VP (VBG reducing) (NP (NN incidence) (JJ AFB-induced) (NN liver) (NN cancer))))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 55:B01.050.150.900.649.801.400.112.400.400 158:D23.101 434:E05.318.308.985.525.375|ES| 2:1 18:1 19:1 36:1 124:1 218:1 237:1 836:1 1269:1 1511:1 2215:1 2361:1 2825:1 2827:1 3039:1 3328:1 3329:1 3330:1 3331:1 3332:1

1 	|BT| (S (NP (NN Claudin-1) (NN overexpression) (JJ intestinal) (JJ epithelial) (NN cell)) (VP (VBZ enhances) (NP (NN susceptibility) (JJ adenamatous) (NN polyposis) (JJ coli-mediated) (NN colon) (NN tumorigenesis)))) |ET| |BS|3:C04.557.470.035.215.100 32:C04.697.098.500 33:C04.697.098 46:A03.556.124.526.356 47:A03.556.124 75:A11.436 401:C23.550.291.687 952:D12.776.543.984.200.100|ES| 19:1 58:1 78:1 94:1 109:1 113:1 127:1 152:1 1353:1 1356:1 3333:1 3334:1 3335:1

1 	|BT| (S (NP (NNP Coffee)) (VP (VBZ reduces) (NP (NP (NN liver) (NN damage) (NN rat) (NN model) (NN steatohepatitis)) (: :) (NP (VBG underlying) (NN mechanism) (NN role) (NNS polyphenols) (NNS melanoidins))))) |ET| |BS|15:F01.829.316.616 56:D02.455.426.559.389.657.715 242:A03.620 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 508:C06.552.241 652:D20.215.784.249|ES| 19:1 31:1 72:1 104:1 142:1 154:1 162:1 435:1 836:1 849:1 1791:1 1848:1 2480:1 2481:1

1 	|BT| (FRAG (ADVP (RB Collectively)) (, ,) (NP (NP (NNS data)) (SBAR (IN along) (S (NP (JJ negative) (NN genotoxicity)) (VP (VBP demonstrate) (SBAR (S (NP (NP (NN oxyfluorfen)) (PRN (-LRB- -LRB-) (NP (ADJP (QP (JJR >) (CD 98)) (NN %)) (NN purity)) (-RRB- -RRB-))) (ADJP (JJ potential)) (VP (VBP induce) (S (NP (NN mouse) (NN liver) (NN tumor)) (ADJP (JJ nongenotoxic)))))) (, ,) (NP (NP (JJ mitogenic) (NNP MOA) (JJ clear) (NN threshold)) (VP (VBD predicted) (NP (JJ carcinogenic) (JJ human) (JJ relevant) (NN exposure) (NN level))))))))) |ET| |BS|8:C04 11:B01.050.150.900.649.865.635.505.500 30:Z01.058.290.190.800 31:D08.811.520.224.800 55:B01.050.150.900.649.801.400.112.400.400 279:D27.888.569.100 515:C04.588.274.623 575:V02.050 953:D27.505.519.593.624|ES| 2:1 7:1 10:1 14:1 19:1 36:1 52:1 243:1 249:1 369:1 449:1 502:1 793:1 827:1 836:1 865:1 1466:1 1872:1 1953:1 2666:1 3336:1 3337:1 3338:1 3339:1 3340:1 3341:1 3342:1 3343:1 3344:1 3345:1 3346:1

1 	|BT| (S (NP (VBN Combined) (NN lapatinib) (NN panobinostat) (NN treatment)) (VP (VBD interacted) (ADVP (RB synergistically)) (VP (VB inhibit) (NP (NP (NN proliferation) (NN colony) (NN formation) (NN CRC) (NN cell) (NN line)) (VP (VBN tested)))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 20:G03.495 30:Z01.058.290.190.800 31:D08.811.520.224.800 52:E02 94:A11.251.210 109:I01.696.116 122:C14.280.383|ES| 19:1 43:1 94:1 245:1 264:1 299:1 314:1 546:1 741:1 1370:1 2488:1 2988:1 3347:1 3348:1 3349:1

1 	|BT| (NP (NP (NN CONCLUSION)) (: :) (S (NP (NP (PRP$ Our) (NNS data)) (VP (VBP indicate) (SBAR (S (NP (JJ sustained) (NN LPS) (NN accumulation)) (VP (VBZ represents) (NP (JJ pathological) (NN mediator) (NP (NP (JJ inflammation-associated) (JJ hepatocellular) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NN HCC)) (-RRB- -RRB-))) (NN manipulation) (NN gut) (NN flora))))))) (VP (VBP prevent) (SBAR (S (NP (JJ pathogenic) (JJ bacterial) (NN translocation) (NN endotoxin) (NN absorption)) (VP (MD may) (ADVP (RB favorably)) (VP (VB influence) (NP (NP (NN liver) (NN function) (NN patient) (NN cirrhosis) (NN risk)) (VP (VBG developing) (NP (NNP HCC))))))))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 50:M01.643 61:E05.318.740.600.800 104:C04.557.470.200.025.255 242:A03.620 327:G06.930 357:C06.552.630 417:H02.403.650 662:C23.550.355 954:G06.755.375 955:G06.755.375 956:D09.400.500 957:G06.099.112.105 958:G01.595.014 959:D23.946.123.329 960:D23.469|ES| 10:1 14:1 19:1 33:1 104:1 120:1 171:1 303:1 304:1 441:1 491:1 590:1 658:1 733:1 793:1 836:1 867:1 1199:1 1426:1 1479:1 1618:1 1698:1 1847:1 1849:1 1882:1 2120:1 2516:1 3350:1 3351:1 3352:1 3353:1 3354:1 3355:1 3356:1 3357:1 3358:1

1 	|BT| (NP (NP (NN CONCLUSION)) (: :) (S (NP (NNP Bromelain)) (VP (VBZ exerts) (NP (NP (JJ antiproliferative) (JJ proapoptotic) (NN effect)) (JJ colorectal) (NN carcinoma) (NN cell) (JJ chemopreventive) (NN action) (NN colon) (NN carcinogenesis)) (FW vivo)))) |ET| |BS|5:C04.588.274.476.411.307 33:C04.697.098 41:A11 46:A03.556.124.526.356 679:D08.811.277.656.262.500.096|ES| 17:1 19:1 75:1 94:1 104:1 113:1 207:1 304:1 378:1 1882:1 1885:1 1946:1 1977:1 2013:1 3120:1 3359:1

1 	|BT| (NP (NP (NN CONCLUSION)) (: :) (S (NP (JJ Functional) (NN interaction) (NN FOXO3a) (NN ER)) (VP (VBP play) (NP (JJ critical) (NN role)) (S (VP (VBG suppressing) (ADVP (NP (JJ estrogen-dependent) (NN breast) (NN cancer) (NN cell) (NN growth) (NN tumorigenesis)) (FW vivo))))))) |ET| |BS|15:F01.829.316.616 32:C04.697.098.500 33:C04.697.098 41:A11 45:G07.700.320.249 79:I03.450.642.693 889:D27.505.696.399.472.277|ES| 18:1 19:1 23:1 31:1 78:1 94:1 102:1 104:1 238:1 378:1 618:1 825:1 1882:1 2250:1 3360:1 3361:1 3362:1 3363:1

1 	|BT| (NP (NP (NN CONCLUSION)) (: :) (NP (NP (NNP Metformin)) (, ,) (VP (ADVP (RB generally)) (VBN considered) (S (ADJP (JJ nontoxic) (SBAR (S (ADJP (RB remarkably) (JJ inexpensive)) (, ,) (VP (MD might) (NP (VBN used) (NN combination) (NNS TKIs) (NN patient) (JJ non-small) (NN cell) (NN lung) (NN cancer)) (, ,) (S (VP (VBG harboring) (S (NP (NN EGFR) (NN mutation)) (VP (VBP overcome) (S (NP (NN TKI) (NN resistance)) (VP (VB prolong) (NP (NN survival)))))))))))))))) |ET| |BS|18:G05.365.590 30:Z01.058.290.190.800 31:D08.811.520.224.800 50:M01.643 96:I03.784 110:C04.588.894.797.520.109.220.249 784:D02.078.370.141.450|ES| 2:1 18:1 19:1 34:1 94:1 104:1 120:1 187:1 274:1 328:1 476:1 530:1 694:1 798:1 1061:1 1094:1 1304:1 1882:1 2746:1 2998:1 3364:1 3365:1 3366:1 3367:1 3368:1 3369:1 3370:1

1 	|BT| (NP (NP (NN CONCLUSION) (: :)) (S (NP (PRP$ Our) (NN result)) (VP (VBP suggest) (SBAR (S (NP (NN garcinol)) (VP (MD may) (VP (VB merit) (S (NP (JJ clinical) (NN investigation) (NN chemoprophylactic) (NN food) (NN help)) (VP (VB prevent) (NP (JJ colitis-associated) (NN colon) (NN cancer))))))))))) |ET| |BS|53:C06.405.205.265 225:E05.337 680:G07.203.300|ES| 18:1 19:1 84:1 101:1 104:1 113:1 410:1 491:1 658:1 733:1 796:1 1497:1 1882:1 2470:1 3371:1 3372:1 3373:1 3374:1

1 	|BT| (S (NP (NN CONCLUSION) (: :)) (VP (VP (VBN Taken) (ADVP (RB together))) (, ,) (SBAR (S (NP (NNS data) (VBP show) (NN Akt) (NN inhibitor) (NN AZD5363)) (VP (VBZ synergizes) (SBAR (S (NP (JJ lysosomotropic) (NN inhibitor) (NN autophagy) (NN chloroquine)) (VP (VBP induce) (NP (NN apoptosis) (NN delay) (NN tumor) (NN progression) (NN prostate) (NN cancer) (NN model) (JJ resistant) (NN monotherapy) (NN AZD5363)) (, ,) (S (VP (VBG providing) (NP (NP (JJ new) (JJ therapeutic) (NN approach)) (RRC (ADVP (RB potentially)) (NP (JJ translatable) (NN patient)))))))))))))) |ET| |BS|8:C04 16:C23.550.291.656 30:Z01.058.290.190.800 31:D08.811.520.224.800 39:G04.299.139.160 50:M01.643 52:E02 202:C04.588.945.440.770 390:G04.299.139.399 961:D03.438.810.050.180|ES| 2:1 7:1 18:1 19:1 48:1 72:1 77:1 89:1 104:1 120:1 136:1 243:1 380:1 427:1 429:1 541:1 712:1 773:1 793:1 911:1 1289:1 1317:1 1537:1 1538:1 1882:1 3025:1 3375:1 3376:1 3377:1 3378:1 3379:1 3380:1

1 	|BT| (NP (NP (NNS CONCLUSIONS) (: :)) (S (NP (DT The) (NN absence) (JJ retinoid-containing) (NN HSC) (NN lipid) (NN droplet)) (VP (VBP promote) (SBAR (S (NP (NN HSC) (NN activation)) (VP (VBZ reduces) (NP (NN hepatocarcinogenesis)))))))) |ET| |BS|711:D02.455.326.271.665.202.495 962:A11.148.378 963:A11.284.430.214.190.875.393|ES| 19:1 104:1 142:1 225:1 239:1 679:1 691:1 900:1 1534:1 2401:1 3381:1 3382:1 3383:1

1 	|BT| (NP (NP (NNS CONCLUSIONS) (: :)) (S (NP (PRP$ Our) (NN result)) (VP (VBP suggest) (SBAR (S (NP (NN Raloxifene) (JJ potent) (NN IL-6) (: /) (NN GP130) (NN inhibitor)) (VP (MD may) (VP (VB chemoprevention) (NP (NP (NN agent) (NN liver) (NN cancer)) (VP (VBG targeting) (NP (JJ persistent) (NN STAT3) (NN signaling))))))))))) |ET| |BS|69:G02.111.087.800 82:D12.644.360.024.342.300 201:D12.644.276.374.465.224 253:E02.319.162 964:D02.455.426.559.389.150.700.900.775|ES| 18:1 19:1 22:1 101:1 104:1 195:1 239:1 251:1 380:1 491:1 616:1 658:1 728:1 796:1 836:1 870:1 3384:1 3385:1 3386:1

1 	|BT| (FRAG (NP (NNS CONCLUSIONS) (: :)) (NP (NN Pitavastatin) (JJ effective) (VBG inhibiting) (NP (JJ early) (NN phase) (JJ obesity-related) (NN liver) (NN tumorigenesis))) (, ,) (ADVP (RB therefore)) (, ,) (NP (MD may) (NP (JJ useful) (NN chemoprevention) (NN liver) (NN cancer) (JJ obese) (NN individual)))) |ET| |BS|32:C04.697.098.500 33:C04.697.098 122:C14.280.383 242:A03.620 253:E02.319.162 493:M01 564:C18.654.726.500|ES| 2:1 18:1 19:1 78:1 104:1 218:1 239:1 491:1 836:1 870:1 880:1 1036:1 1128:1 1639:1 2467:1 2468:1 2512:1 2529:1 3387:1

1 	|BT| (NP (NP (NNS CONCLUSIONS) (: :)) (VP (VBN Taken) (ADVP (RB together))) (, ,) (S (NP (NNS data)) (VP (VBP provide) (NP (NP (JJ first) (ADJP (FW vitro) (FW vivo)) (NN evidence) (JJ integral) (NN role)) (NP (NN LKB1-AMPK) (NN axis) (JJ honokiol-mediated) (NN inhibition) (NN invasion) (NN migration) (NN breast) (NN cancer) (NN cell)))))) |ET| |BS|15:F01.829.316.616 43:F01.145.544 579:A02.835.232.834.151.383 681:G04.299.283|ES| 2:1 18:1 19:1 23:1 31:1 38:1 94:1 103:1 104:1 216:1 239:1 378:1 514:1 620:1 711:1 793:1 816:1 1537:1 1538:1 2089:1 2269:1 3388:1 3389:1

1 	|BT| (S (NP (NNS CONCLUSIONS)) (: :) (NP (DT This) (NN study)) (VP (VBD showed) (SBAR (S (NP (NN 5-LOX)) (VP (VBD up-regulated) (NP (NP (JJ adenomatous) (NN colon) (NN polyp) (NN cancer)) (NP (VBN compared) (JJ normal) (JJ colonic) (NN mucosa)))))))) |ET| |BS|46:A03.556.124.526.356 142:I01.880.604 150:Z01.542.248.960 302:A10.615.550 548:D08.811.682.664.500.848 551:C04.557.470.035.215|ES| 18:1 19:1 50:1 57:1 104:1 113:1 118:1 131:1 132:1 239:1 579:1 647:1 677:1 807:1 1301:1 3390:1

1 	|BT| (S (NP (JJ Conditional) (NN beta-catenin) (NN loss) (NN mouse)) (VP (VBZ promotes) (NP (NP (NN chemical) (NN hepatocarcinogenesis)) (: :) (NP (NN role) (NP (ADJP (JJ oxidative) (NN stress) (JJ platelet-derived)) (NN growth) (NN factor) (NN receptor) (NN alpha/phosphoinositide) (NN 3-kinase)) (NN signaling))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 15:F01.829.316.616 23:D12.776.091.249 69:G02.111.087.800 578:D08.811.913.696.620.550 716:G03.495.710 965:D08.811.913.696.620.682.725.400.900|ES| 19:1 31:1 32:1 52:1 60:1 102:1 104:1 185:1 186:1 195:1 298:1 900:1 2124:1 2522:1 2583:1 3391:1 3392:1 3393:1 3394:1

1 	|BT| (NP (NP (NP (JJ Consistent) (NN finding) (, ,) (JJ ABCB5-expressing) (NN tumor) (NN cell) (NN population)) (RRC (ADVP (RB also)) (NP (NN treatment) (ADJP (JJ refractory) (S (VP (VBD exhibited) (NP (NN resistance) (JJ 5-FU-induced) (NN apoptosis) (JJ colorectal) (NN cancer) (NN xenograft) (NN model) (NN 5-FU) (NN monotherapy))))))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 8:C04 39:G04.299.139.160 41:A11 52:E02 92:E04.936.764 93:A01.941.875 175:J01.897.280.500.269 275:C23.888 560:D03.383.742.698.875.404 829:M01.686 966:N01.600|ES| 2:1 5:1 7:1 17:1 18:1 19:1 72:1 89:1 94:1 265:1 546:1 609:1 927:1 1094:1 2023:1 2308:1 3379:1 3395:1 3396:1 3397:1 3398:1

1 	|BT| (NP (NP (NP (JJ Constitutive) (NN activation) (NN phosphoinositide) (NN 3-kinase)) (PRN (-LRB- -LRB-) (NP (NN PI3K)) (-RRB- -RRB-))) (: -) (S (NP (NN Akt) (NN pathway)) (VP (VBZ transmits) (NP (NP (JJ growth-regulatory) (NN signal) (NN play) (JJ central) (NN role)) (S (VP (VBG promoting) (NP (NP (NN survival)) (, ,) (NP (NN proliferation)) (, ,) (NP (NN angiogenesis) (JJ human) (NN prostate) (NN cancer) (NN cell))))))))) |ET| |BS|15:F01.829.316.616 41:A11 45:G07.700.320.249 55:B01.050.150.900.649.801.400.112.400.400 79:I03.450.642.693 96:I03.784 378:D08.811.913.696.620.682.700.755 578:D08.811.913.696.620.550|ES| 2:1 10:1 14:1 18:1 19:1 31:1 36:1 77:1 94:1 225:1 238:1 274:1 299:1 383:1 859:1 881:1 2080:1 2502:1 3235:1 3394:1 3399:1 3400:1 3401:1 3402:1 3403:1

1 	|BT| (S (NP (JJ Constitutive) (NN activation) (NN Wnt/beta-catenin) (NN pathway)) (VP (VBN implicated) (NP (JJ primary) (NN cause) (NN colon) (NN cancer)))) |ET| |BS|23:D12.776.091.249 147:G02.149.115.800.925|ES| 18:1 19:1 113:1 225:1 302:1 344:1 383:1 977:1 1779:1 3399:1

1 	|BT| (S (ADVP (RB Conversely)) (, ,) (NP (NP (JJ partial) (NN loss) (NN A20)) (, ,) (NP (NN A20) (NN heterozygote) (NN mouse)) (, ,)) (ADVP (RB significantly)) (VP (VBZ impairs) (NP (NP (NN liver) (NN regeneration) (NN damage)) (, ,) (NP (VP (VBZ confers) (NP (JJ high) (NN lethality)) (S (VP (ADVP (RB otherwise)) (NP (JJ safe) (NN procedure))))) (NP (FW i.e.) (, ,) (CD 2/3) (JJ partial) (NN hepatectomy)))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 157:G05.380.383 375:Z01.639.100 925:G10.261.326.520 928:E04.210.556 967:D01.248.497.158.490|ES| 2:1 19:1 32:1 52:1 124:1 178:1 836:1 1508:1 1826:1 1848:1 2729:1 2737:1 3260:1 3272:1 3273:1 3404:1 3405:1 3406:1 3407:1 3408:1 3409:1 3410:1

1 	|BT| (S (NP (NN Cooperativity) (NN E-cadherin) (NN Smad4) (NN loss)) (VP (VBP promote) (NP (JJ diffuse-type) (JJ gastric) (NN adenocarcinoma) (NN metastasis)))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 70:A03.556.875.875 84:C04.557.470.200.025 113:C04.697.650 613:D12.776.395.550.200.200 968:F01.145.813.115|ES| 19:1 32:1 86:1 255:1 521:1 679:1 806:1 2267:1 3411:1 3412:1

1 	|BT| (NP (NP (NN Correlation) (NN Wnt-2) (NN expression) (NN beta-catenin) (JJ intracellular) (NN accumulation) (JJ Chinese) (JJ gastric) (NN cancer)) (: :) (NP (NN relevance) (NN tumour) (NN dissemination))) |ET| |BS|8:C04 23:D12.776.091.249 924:A11.284.430.214|ES| 18:1 19:1 60:1 86:1 104:1 115:1 795:1 1011:1 2120:1 2763:1 3252:1 3324:1 3413:1 3414:1

1 	|BT| (NP (NP (JJ Critical) (NN function) (NN ADAM9) (NN mouse) (NN prostate) (NN cancer))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500|ES| 18:1 19:1 33:1 52:1 77:1 3211:1 3415:1

1 	|BT| (NP (NP (NN Cross-talk) (NN aryl) (NN hydrocarbon) (NN receptor) (JJ mitogen-activated) (NN protein) (NN kinase) (NN signaling) (NN pathway) (NN liver) (NN cancer) (NN c-raf) (JJ transcriptional) (NN regulation))) |ET| |BS|69:G02.111.087.800 126:G02.111.087.800 142:I01.880.604 148:G12.425.143.281 209:G02.111.087.847 478:D08.811.913.696.620.682.700.567 969:D12.776.260.643.715|ES| 4:1 18:1 19:1 186:1 195:1 383:1 438:1 470:1 559:1 836:1 3295:1 3416:1 3417:1 3418:1 3419:1

1 	|BT| (S (NP (NN Cryptotanshinone)) (VP (VBZ inhibits) (NP (NP (JJ constitutive) (NN signal) (NN transducer) (NN activator) (NN transcription) (CD 3) (NN function)) (VP (VBG blocking) (NP (NN dimerization) (NN DU145) (NN prostate) (NN cancer) (NN cell)))))) |ET| |BS|41:A11 122:C14.280.383 209:G02.111.087.847 250:E07.305.812 970:E06.658.453.560.100 971:G02.149.250|ES| 18:1 19:1 33:1 77:1 94:1 487:1 604:1 615:1 859:1 860:1 861:1 862:1 3420:1 3421:1 3422:1 3423:1

1 	|BT| (S (NP (NNP Cryptotanshinone)) (ADVP (RB rapidly)) (VP (VBD inhibited) (NP (NN STAT3) (NN Tyr705) (NN phosphorylation) (NN DU145) (NN prostate) (NN cancer) (NN cell) (NN growth) (NN cell)) (NP (CD 96) (NN hour) (NN treatment)))) |ET| |BS|41:A11 45:G07.700.320.249 52:E02 82:D12.644.360.024.342.300 122:C14.280.383 972:G02.111.087.677|ES| 18:1 19:1 77:1 94:1 102:1 251:1 365:1 546:1 3420:1 3423:1 3424:1 3425:1 3426:1 3427:1 3428:1

1 	|BT| (S (NP (NN Curcumin)) (VP (VBZ sensitizes) (NP (NP (JJ human) (JJ colorectal) (NN cancer) (NN xenograft) (JJ nude) (NN mouse) (NN gamma-radiation)) (VP (VBG targeting) (NP (JJ nuclear) (JJ factor-kappaB-regulated) (NN gene) (NN product)))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 30:Z01.058.290.190.800 31:D08.811.520.224.800 55:B01.050.150.900.649.801.400.112.400.400 88:B01.050.150.900.649.865.635.505.500.550.500 92:E04.936.764 93:A01.941.875 142:I01.880.604 210:D12.776.260.600 692:D02.455.326.146.485.222.222 816:G01.358.500.505.300 973:E05.393.335|ES| 9:1 17:1 18:1 19:1 36:1 52:1 265:1 266:1 616:1 675:1 1256:1 2062:1 3429:1 3430:1 3431:1

1 	|BT| (NP (NP (NP (NN Cyclooxygenase) (CD 2) (NN play) (JJ critical) (NN role) (NN development) (JJ gastrointestinal) (NN cancer)) (NP (JJ human) (NN animal) (NN model)))) |ET| |BS|15:F01.829.316.616 24:D08.811.600.720.750 55:B01.050.150.900.649.801.400.112.400.400 79:I03.450.642.693 285:E05.598|ES| 18:1 19:1 31:1 35:1 36:1 46:1 72:1 148:1 183:1 238:1 825:1 3432:1

1 	|BT| (S (NP (NP (NN Cyclooxygenase-2)) (PRN (-LRB- -LRB-) (NP (NN COX-2)) (-RRB- -RRB-))) (ADVP (RB constitutively)) (VP (VBD expressed) (NP (NP (NN variety) (NN tumor)) (PP (VBG including) (NP (JJ colorectal) (NN cancer)))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 8:C04 24:D08.811.600.720.750|ES| 6:1 7:1 10:1 14:1 17:1 18:1 19:1 76:1 196:1 561:1 952:1 1158:1

1 	|BT| (S (NP (NN Decrease) (JJ hepatic) (JJ stellate) (NN cell) (NN rat)) (VP (VBD enhanced) (NP (NN sensitivity) (JJ clofibrate-induced) (NN hepatocarcinogenesis)))) |ET| |BS|245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 677:A11.561 910:D02.241.081.114.968.500.500.195|ES| 19:1 94:1 385:1 607:1 838:1 849:1 900:1 2461:1 3433:1 3434:1

1 	|BT| (FRAG (NP (NN Deficiency) (NN folate)) (, ,) (NP (S (VP (VBP play) (NP (NN role) (NN synthesis) (NNP SAM) (NN lead)))) (NP (VBD increased) (NN risk) (NN colon) (NN cancer)))) |ET| |BS|15:F01.829.316.616 20:G03.495 61:E05.318.740.600.800 79:I03.450.642.693 86:D01.268.556.435 232:D02.886.030.676.180 974:C18.654.521.500.133.699.308|ES| 2:1 18:1 19:1 31:1 47:1 113:1 171:1 238:1 254:1 778:1 3435:1 3436:1 3437:1

1 	|BT| (NP (NP (JJ Desmoplakin) (NN act) (NN tumor) (NN suppressor) (NN inhibition) (NN Wnt/beta-catenin) (NN signaling) (NN pathway) (JJ human) (NN lung) (NN cancer))) |ET| |BS|38:Z01.058.290.120.180 40:Z01.542.248.700 43:F01.145.544 55:B01.050.150.900.649.801.400.112.400.400 81:E02.095.465.425.400.330.050.400 105:G02.149.115.800.925 206:G05.360.340.024.340.375.249 975:D12.776.220.790.500|ES| 7:1 18:1 19:1 36:1 103:1 195:1 246:1 302:1 328:1 383:1 700:1 3438:1

1 	|BT| (S (NP (JJ Diet-induced) (NN obesity) (NN ethanol)) (VP (VBP impair) (NP (NN progression) (JJ hepatocellular) (NN carcinoma) (NN mouse) (JJ mesenteric) (NN vein) (NN injection) (NN model)))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 16:C23.550.291.656 104:C04.557.470.200.025.255 226:E02.319.267.530 564:C18.654.726.500 595:G07.203.650.240 596:E02.642.249 751:D02.033.375 976:A07.231.908.670.385|ES| 19:1 48:1 52:1 72:1 303:1 304:1 785:1 2010:1 3439:1 3440:1 3441:1 3442:1 3443:1

1 	|BT| (S (VP (NP (NNP Digital)) (VBG karyotyping) (VP (VBZ identifies) (NP (NN thymidylate) (NN synthase) (NN amplification) (NN mechanism) (NN resistance) (NN 5-fluorouracil) (JJ metastatic) (JJ colorectal) (NN cancer) (NN patient))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 30:Z01.058.290.190.800 31:D08.811.520.224.800 50:M01.643 560:D03.383.742.698.875.404 712:E01.370.225.500.385.315 713:D08.811.913.555.500.862 714:A01.378.800.667.430|ES| 17:1 18:1 19:1 66:1 120:1 162:1 337:1 921:1 1094:1 1610:1 2307:1 2576:1 2577:1 2578:1

1 	|BT| (NP (NP (NN Disruption) (NN Ptk6) (NN decrease) (JJ azoxymethane-induced) (NN colon) (NN tumorigenesis) (NN mouse))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 32:C04.697.098.500 33:C04.697.098 46:A03.556.124.526.356 132:D02.172.080|ES| 19:1 52:1 78:1 113:1 295:1 2533:1 3444:1 3445:1

1 	|BT| (S (NP (NN DNA) (NN methylation) (NN alteration)) (VP (VBD detected) (SBAR (S (NP (NN zebrafish) (NN liver) (NN tumor)) (VP (VBD induced) (NP (NP (JJ environmental) (NN carcinogen) (CD 7)) (, ,) (NP (JJ 12-dimethylbenz) (-LRB- -LRB-) (-RRB- -RRB-) (NN anthracene)))))))) |ET| |BS|366:G02.111.087.029.538.161 515:C04.588.274.623 572:B01.050.150.900.493.200.244.828 977:D27.888.569.100.125|ES| 2:1 7:1 10:1 14:1 19:1 81:1 412:1 666:1 836:1 951:1 988:1 1007:1 2017:1 2125:1 3446:1 3447:1 3448:1

1 	|BT| (S (NP (NNP Dovitinib)) (ADVP (RB also)) (VP (VP (VBD caused) (NP (NP (NP (NN dephosphorylation) (NN retinoblastoma)) (, ,) (NP (NN upregulation) (NN p-histone) (NN H2A-X) (NN p27)) (, ,)) (NN downregulation) (NN p-cdk-2) (NN cyclin) (NN B1))) (, ,) (VP (VBD resulted) (NP (NN reduction) (JJ cellular) (NN proliferation) (NN induction) (NN tumor) (NN cell) (NN apoptosis))))) |ET| |BS|8:C04 39:G04.299.139.160 41:A11 85:G02.111.087.225 183:G04.299.233.750 249:G05.355.315.800 339:G02.111.087.880 510:C23.550.444 978:D08.811.913.696.620.682.700.646.500 979:D12.644.360.262.120.100 980:C04.557.465.625.600.725|ES| 2:1 5:1 7:1 19:1 89:1 94:1 299:1 370:1 594:1 595:1 736:1 743:1 1124:1 1126:1 2506:1 3074:1 3449:1 3450:1 3451:1 3452:1 3453:1 3454:1 3455:1

1 	|BT| (S (NP (NNP Dovitinib)) (VP (VBZ demonstrates) (NP (JJ antitumor) (JJ antimetastatic) (NN activity) (NN xenograft) (NN model) (JJ hepatocellular) (NN carcinoma)))) |ET| |BS|92:E04.936.764 93:A01.941.875 104:C04.557.470.200.025.255|ES| 19:1 72:1 265:1 303:1 304:1 399:1 2244:1 2245:1 2541:1 3449:1

1 	|BT| (S (NP (NP (NN Downregulation) (JJ tumor-suppressor) (NN miR-16)) (PP (IN via) (NP (JJ progestin-mediated) (JJ oncogenic) (NN signaling)))) (VP (VBZ contributes) (NP (NN breast) (NN cancer) (NN development)))) |ET| |BS|69:G02.111.087.800 85:G02.111.087.225 206:G05.360.340.024.340.375.249 279:D27.888.569.100 981:D27.505.696.399.472.858|ES| 18:1 19:1 23:1 35:1 195:1 296:1 596:1 845:1 953:1 1156:1 3456:1 3457:1

1 	|BT| (NP (NP (NN Down-regulation) (NN tumor) (NN suppressor) (NN A) (NN kinase) (NN anchor) (NN protein) (CD 12) (JJ human) (NN hepatocarcinogenesis) (JJ epigenetic) (NN mechanism))) |ET| |BS|55:B01.050.150.900.649.801.400.112.400.400 85:G02.111.087.225 206:G05.360.340.024.340.375.249 671:G05.355.315.203 823:D08.811.913.696.620.682.700.150.125|ES| 4:1 7:1 19:1 36:1 69:1 162:1 470:1 700:1 900:1 1120:1 1603:1 3458:1 3459:1

1 	|BT| (S (VP (VBN Dysregulated) (SBAR (S (NP (JJ Kruppel-like) (NN factor) (CD 4) (NN vitamin) (NN D) (NN receptor) (NN signaling)) (VP (VBP contribute) (NP (NN progression) (JJ hepatocellular) (NN carcinoma))))))) |ET| |BS|16:C23.550.291.656 69:G02.111.087.800 104:C04.557.470.200.025.255 982:D12.776.826.535|ES| 19:1 48:1 185:1 186:1 195:1 303:1 304:1 318:1 319:1 450:1 2591:1 2592:1 3460:1

1 	|BT| (S (NP (NNS Effects)) (VP (VBP magnolol) (NP (NP (JJ UVB-induced) (NN skin) (NN cancer) (NN development) (NN mouse)) (JJ possible) (NN mechanism) (NN action)))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 742:G03.787|ES| 18:1 19:1 35:1 52:1 162:1 1359:1 2013:1 2319:1 2526:1 2752:1 3461:1

1 	|BT| (NP (NP (NNS Effects) (JJ S-adenosylmethionine) (NN methylthioadenosine) (JJ inflammation-induced) (NN colon) (NN cancer) (NN mouse))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 53:C06.405.205.265 232:D02.886.030.676.180 525:C23.550.470|ES| 18:1 19:1 52:1 113:1 1793:1 3461:1 3462:1 3463:1

1 	|BT| (S (NP (JJ Elevated) (NN expression) (JJ coactivator-associated) (NN arginine) (NN methyltransferase) (CD 1)) (VP (VBN associated) (NP (JJ early) (NN hepatocarcinogenesis)))) |ET| |BS||ES| 19:1 98:1 115:1 169:1 900:1 1128:1 1350:1 2655:1 3464:1 3465:1

1 	|BT| (NP (NP (NP (VBN Enhanced) (NN liver) (NN tumor) (NN promotion) (NN liver) (NN initiation) (NN activity)) (NP (NN rat) (VBN subjected) (JJ combined) (NN administration) (NN omeprazole) (NN beta-naphthoflavone)))) |ET| |BS|242:A03.620 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 515:C04.588.274.623 618:E02.186 983:D03.383.663.283.266.450.175.100 984:D02.886.640.074.500|ES| 7:1 19:1 164:1 399:1 637:1 836:1 849:1 2337:1 2575:1 3267:1 3466:1 3467:1 3468:1

1 	|BT| (NP (NP (JJ Epigenetic) (NN identification) (NN ubiquitin) (JJ carboxyl-terminal) (NN hydrolase) (NN L1) (JJ functional) (NN tumor) (NN suppressor) (NN biomarker) (JJ hepatocellular) (NN carcinoma) (JJ digestive) (NN tumor))) |ET| |BS|104:C04.557.470.200.025.255 158:D23.101 206:G05.360.340.024.340.375.249 244:C04.588.274.476 374:F01.393.446 985:D08.811.277.352.897.850 986:C04.588.274|ES| 7:1 19:1 303:1 304:1 415:1 700:1 885:1 1201:1 3469:1 3470:1 3471:1 3472:1 3473:1 3474:1

1 	|BT| (FRAG (NP (NP (NN ErbB2) (NN ErbB3) (NN receptor) (NN tyrosine) (NN kinase)) (NP (VBN associated) (NN development) (JJ human) (NN colon) (NN cancer)) (, ,) (NP (NN expression) (NN receptor) (JJ high) (NN HT-29) (NN cell)))) |ET| |BS|55:B01.050.150.900.649.801.400.112.400.400 792:A11.251.210.190.475 987:D08.811.913.696.620.682.725.400|ES| 2:1 18:1 19:1 35:1 36:1 94:1 113:1 115:1 169:1 178:1 186:1 470:1 1705:1 2341:1 2782:1 3475:1

1 	|BT| (NP (NP (JJ Essential) (NN contribution) (NN chemokine)) (, ,) (NP (NN CCL3)) (, ,) (NP (NN receptor)) (, ,) (NP (NN CCR1)) (, ,) (NP (JJ hepatocellular) (NN carcinoma) (NN progression))) |ET| |BS|16:C23.550.291.656 104:C04.557.470.200.025.255 313:D12.644.276.374.200|ES| 2:1 19:1 48:1 186:1 303:1 304:1 1360:1 3476:1 3477:1 3478:1 3479:1

1 	|BT| (NP (NP (JJ EXPERIMENTAL) (NN DESIGN)) (: :) (S (PP (IN In) (NP (JJ present) (NN study))) (, ,) (VP (VBD investigated) (NP (NP (NP (NN effect) (JJ novel) (NN farnesyltransferase) (NN inhibitor)) (, ,) (NP (NN ABT-100)) (, ,) (NP (JJ human) (NN liver) (NN cancer) (NN cell) (NN line))) (, ,) (NP (NN HepG2) (NN Huh7)) (, ,) (NP (NN animal) (NN model) (NN hepatocarcinogenesis)))))) |ET| |BS|55:B01.050.150.900.649.801.400.112.400.400 94:A11.251.210 204:E05.581.500 205:E05.581.500 259:D12.776.395.240.150.500 285:E05.598 988:D08.811.913.225.431 989:D08.811.913.225.437 990:C22.232|ES| 2:1 18:1 19:1 36:1 46:1 72:1 75:1 94:1 104:1 131:1 244:1 264:1 380:1 403:1 689:1 690:1 836:1 891:1 900:1 1307:1 2538:1 3480:1 3481:1 3482:1

1 	|BT| (NP (NP (NP (NN Expression) (NP (JJ ets-related) (JJ transcriptional) (NN factor)) (NN E1AF) (VBN associated) (NN tumor) (NN progression) (NN over-expression) (NN matrilysin)) (NP (JJ human) (JJ gastric) (NN cancer)))) |ET| |BS|8:C04 16:C23.550.291.656 55:B01.050.150.900.649.801.400.112.400.400 166:D12.776.930 937:D08.811.277.656.300.480.525.700.250|ES| 7:1 18:1 19:1 36:1 48:1 86:1 169:1 185:1 316:1 559:1 1013:1 3289:1 3483:1 3484:1

1 	|BT| (S (NP (NN Expression) (NN glutathione) (NN peroxidase) (CD 2)) (VP (VBN associated) (NP (JJ early) (NN hepatocarcinogenesis)) (ADVP (RB also)) (NP (JJ late) (NN stage) (NN metastasis)))) |ET| |BS|113:C04.697.650 991:D08.811.682.732.500|ES| 5:1 19:1 148:1 169:1 316:1 806:1 900:1 1128:1 1129:1 2649:1 2744:1 3485:1

1 	|BT| (S (NP (NN Expression) (NN protein) (NN kinase) (NN C)) (VP (NNS isoenzymes) (NP (JJ colorectal) (NN cancer) (NN tissue) (JJ differential) (NN activation) (JJ different) (NN bile) (NN acid)))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 98:A10 992:D08.811.913.696.620.682.700.725 993:D08.811.348 994:D04.808.105|ES| 4:1 17:1 18:1 19:1 225:1 272:1 316:1 414:1 470:1 1275:1 1621:1 1677:1 1955:1 3486:1

1 	|BT| (NP (NP (NP (NNP Farnesyltransferase) (NN inhibitor)) (, ,) (NP (NN ABT-100)) (, ,) (NP (JJ potent) (NN liver) (NN cancer) (JJ chemopreventive) (NN agent)))) |ET| |BS|988:D08.811.913.225.431 989:D08.811.913.225.437|ES| 2:1 18:1 19:1 22:1 380:1 728:1 836:1 1946:1 2538:1 3487:1

1 	|BT| (S (ADVP (RB Finally)) (, ,) (NP (NN Apo-FHL2) (NN mouse)) (VP (VBD developed) (SBAR (S (NP (NP (NN tumor)) (, ,) (NP (NN FHL2) (NN transgene))) (VP (VBD enhanced) (SBAR (S (NP (NN hepatocarcinogenesis)) (VP (VBD induced) (NP (JJ liver-specific) (NN deletion) (NP (NP (JJ adenomatous) (NN polyposis) (NN coli) (NN gene) (JJ aberrant) (NN Wnt/beta-catenin) (NN signaling) (NN Apc)) (PRN (-LRB- -LRB-) (NP (NN lox/lox)) (-RRB- -RRB-))) (NN animal)))))))))) |ET| |BS|3:C04.557.470.035.215.100 8:C04 11:B01.050.150.900.649.865.635.505.500 19:B01.050 21:G05.360.340.024.340.375.249.050 105:G02.149.115.800.925 242:A03.620 547:G05.360.340.024.340.825 548:D08.811.682.664.500.848 549:G05.355.600.800.320|ES| 2:1 7:1 9:1 10:1 14:1 19:1 46:1 52:1 57:1 58:1 59:1 195:1 280:1 302:1 385:1 412:1 900:1 1059:1 1165:1 1725:1 1799:1 1929:1 1930:1 1931:1 1932:1 1933:1

1 	|BT| (NP (NP (NNP Folate) (NN transport) (NN gene) (NN inactivation) (NN mouse) (NN increase) (NN sensitivity) (NN colon) (NN carcinogenesis))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 33:C04.697.098 42:G05.355.315.203.374 46:A03.556.124.526.356 224:D03.438.733.631.400 947:G03.495.166|ES| 9:1 19:1 40:1 52:1 113:1 207:1 607:1 1314:1 3318:1 3488:1

1 	|BT| (S (PP (IN For) (NP (NN example))) (, ,) (NP (NP (NN gene) (VBN involved) (NN inflammation) (NN matrix) (NN protease) (NN cell) (NN cycle) (NN regulator) (NN gene)) (, ,) (NP (NN cyclin) (NN D2)) (, ,)) (ADVP (RB highly)) (VP (VBN expressed) (NP (NN colon) (NN cancer)))) |ET| |BS|6:G05.360.340.024.340 525:C23.550.470 995:D12.644.360.262.150.200 996:G05.360.340.024.340.220 997:D08.811.277.656.300 998:D08.811.277.656|ES| 2:1 6:1 9:1 18:1 19:1 94:1 113:1 235:1 601:1 626:1 743:1 774:1 3064:1 3489:1 3490:1 3491:1 3492:1 3493:1

1 	|BT| (S (NP (NN Forkhead) (NN box) (NN transcription) (NN factor) (NN FOXO3a)) (VP (VBZ suppresses) (NP (JJ estrogen-dependent) (NN breast) (NN cancer) (NN cell) (NN proliferation) (NN tumorigenesis)))) |ET| |BS|32:C04.697.098.500 33:C04.697.098 166:D12.776.930 183:G04.299.233.750 889:D27.505.696.399.472.277|ES| 18:1 19:1 23:1 78:1 94:1 185:1 299:1 487:1 686:1 1918:1 3361:1 3363:1 3494:1

1 	|BT| (S (NP (NP (NNP Gefitinib)) (, ,) (NP (NN EGFR) (NN inhibitor)) (, ,)) (VP (VBZ prevents) (NP (JJ hepatocellular) (NN carcinoma) (NN development) (NN rat) (NN liver) (NN cirrhosis)))) |ET| |BS|104:C04.557.470.200.025.255 242:A03.620 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 357:C06.552.630 662:C23.550.355|ES| 2:1 19:1 35:1 187:1 303:1 304:1 380:1 836:1 849:1 1199:1 2718:1 3024:1

1 	|BT| (S (NP (NNS Genes)) (VP (VBD expressed) (NP (NP (NN PB) (CD two) (NNS conazoles)) (RRC (ADVP (RB also)) (NP (VBN compared) (NP (NN gene) (VBN associated) (JJ human) (JJ hepatocellular) (NN cancer))))))) |ET| |BS|6:G05.360.340.024.340 55:B01.050.150.900.649.801.400.112.400.400|ES| 5:1 6:1 9:1 18:1 19:1 36:1 50:1 169:1 303:1 933:1 3495:1 3496:1 3497:1

1 	|BT| (SINV (NP (NP (NNP Geraniol)) (, ,) (NP (NN component) (NN plant) (JJ essential) (NN oil)) (, ,)) (VP (VBZ modulates) (NP (NN DNA) (NN synthesis))) (VP (VBZ potentiates) (NP (NN 5-fluorouracil) (NN efficacy) (JJ human) (NN colon) (NN tumor) (NN xenograft)))) |ET| |BS|51:C04.588.274.476.411.307.180 55:B01.050.150.900.649.801.400.112.400.400 78:G02.111.087.222 92:E04.936.764 93:A01.941.875 560:D03.383.742.698.875.404 999:D10.627.675 1000:A18|ES| 2:1 7:1 19:1 36:1 113:1 265:1 606:1 666:1 1021:1 1098:1 1776:1 2304:1 2307:1 2499:1 2614:1 3436:1 3498:1

1 	|BT| (S (NP (NN Glycine) (NN soya) (NN diet)) (ADVP (RB synergistically)) (VP (VBZ enhances) (SBAR (S (NP (JJ suppressive) (NN effect) (NN tamoxifen)) (VP (VBZ inhibits) (NP (NP (JJ tamoxifen-promoted) (NN hepatocarcinogenesis)) (JJ 7,12-dimethylbenz) (PRN (-LRB- -LSB-) (NP (NN alpha)) (-RRB- -RSB-)) (JJ anthracene-induced) (NN rat) (JJ mammary) (NN tumor) (NN model))))))) |ET| |BS|122:C14.280.383 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 408:C04.588.531 595:G07.203.650.240 596:E02.642.249 640:D02.455.426.559.389.150.700.900 1001:B01.650.940.800.575.100.401.750 1002:C04.588.180 1003:D12.125.481|ES| 7:1 19:1 72:1 75:1 615:1 849:1 900:1 1356:1 1373:1 1378:1 1836:1 1974:1 2191:1 2248:1 2371:1 3349:1 3499:1 3500:1 3501:1 3502:1 3503:1

1 	|BT| (NP (NP (JJ Hepatoprotective) (NN effect) (NN tamoxifen) (NN steatosis) (JJ non-alcoholic) (NN steatohepatitis) (NN mouse) (NN model))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 508:C06.552.241 509:C06.552.241.519 640:D02.455.426.559.389.150.700.900|ES| 19:1 52:1 72:1 75:1 1791:1 2069:1 2371:1 2678:1 3504:1

1 	|BT| (S (VP (ADVP (RB Here)) (VBP show) (SBAR (S (NP (NP (JJ ATP-binding) (NN cassette) (NN member) (NN B5)) (PRN (-LRB- -LRB-) (NP (NN ABCB5)) (-RRB- -RRB-))) (VP (VBZ identifies) (NP (NP (JJ therapy-refractory) (NN tumor) (NN cell) (JJ colorectal) (NN cancer) (NN patient)) (PP (VBG following) (NP (NP (NN fluorouracil)) (PRN (-LRB- -LRB-) (NP (NN 5-FU)) (-RRB- -RRB-)))))))) (: -) (S (NP (VBN based) (NN chemoradiation) (NN therapy)) (VP (VBP provide) (NP (NP (NN evidence)) (JJ functional) (NN role) (NN ABCB5) (JJ colorectal) (NN cancer) (NN 5-FU) (NN resistance)))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 8:C04 15:F01.829.316.616 50:M01.643 52:E02 59:E02.186.079 333:D01.045 560:D03.383.742.698.875.404 1004:E02.095.147|ES| 7:1 10:1 14:1 17:1 18:1 19:1 31:1 38:1 94:1 120:1 130:1 400:1 415:1 429:1 711:1 769:1 1094:1 1610:1 2308:1 2895:1 2919:1 3505:1 3506:1 3507:1 3508:1 3509:1 3510:1 3511:1

1 	|BT| (S (ADVP (RB Here)) (, ,) (VP (VBP provide) (NP (NP (NP (NN evidence) (NN periostin) (, ,) (NN protein) (JJ structural) (NN sequence) (NN homology) (JJ TGF-beta-inducible) (NN gene)) (, ,) (NP (NN beta) (NN ig-h3)) (, ,)) (VP (VBN upregulated) (NP (JJ colorectal) (NN cancer) (NN liver) (NN metastasis)))) (, ,) (VP (MD may) (VP (VB play) (NP (NN role)) (S (VP (VBG promoting) (NP (NN growth) (NN tumor)))))))) |ET| |BS|4:C04.588.274.476.411.307 6:G05.360.340.024.340 8:C04 15:F01.829.316.616 45:G07.700.320.249 79:I03.450.642.693 112:D12.776.097.820 113:C04.697.650 242:A03.620 503:D12.644.276.374.687 1005:G02.111.810|ES| 2:1 4:1 7:1 9:1 17:1 18:1 19:1 31:1 38:1 102:1 125:1 238:1 293:1 400:1 491:1 711:1 806:1 836:1 881:1 1972:1 3512:1 3513:1 3514:1 3515:1 3516:1

1 	|BT| (UCP (ADVP (RB Here)) (, ,) (NP (NP (NN report) (NN identification) (JJ hepatic) (NNS microRNAs)) (SBAR (S (NP (VBN dysregulated) (JJ early) (NN stage) (S (VP (VBG feeding) (NP (NP (NP (NN C57BL/6) (NN mouse) (JJ choline-deficient) (NN amino) (JJ acid-defined)) (-LRB- -LRB-) (JJ CDAA) (-RRB- -RRB-) (NN diet)) (ADJP (VBN known)))))) (VP (VBP promote) (FRAG (NP (NP (JJ nonalcoholic) (NN steatohepatitis)) (PRN (-LRB- -LRB-) (NP (NN NASH)) (-RRB- -RRB-))) (: -) (NP (VBN induced) (NN hepatocarcinogenesis) (CD 84) (NN week)))))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 184:D13.150.650.319 374:F01.393.446 509:C06.552.241.519 593:B01.050.050.199.520.520.420 594:D02.033.100.291.211 595:G07.203.650.240 596:E02.642.249 597:D12.125|ES| 2:1 10:1 14:1 19:1 52:1 400:1 409:1 417:1 556:1 679:1 783:1 838:1 900:1 1128:1 1129:1 1259:1 1791:1 1796:1 2188:1 2189:1 2190:1 2191:1 2192:1 2942:1 3065:1 3184:1 3469:1 3517:1 3518:1

1 	|BT| (S (ADVP (RB Here)) (, ,) (NP (NN report) (NNP MPA)) (ADVP (RB also)) (VP (VBZ induces) (NP (NP (NN differentiation) (JJ androgen-independent) (NN prostate) (NN cancer)) (NP (VBN derived) (NN cell) (NN line) (NN DU145))))) |ET| |BS|74:G04.299.151 94:A11.251.210 852:C04.588.945.440.770.500|ES| 2:1 5:1 18:1 19:1 77:1 94:1 214:1 215:1 264:1 400:1 417:1 1721:1 3423:1 3519:1 3520:1

1 	|BT| (S (ADVP (RB Herein)) (, ,) (VP (VBD found) (SBAR (IN whereas) (S (VP (VBG sparing) (NP (NP (JJ normal) (NP (JJ human) (NN colon) (JJ mucosal) (JJ epithelial) (NN cell))) (, ,) (NP (NN EPLE))) (VP (ADVP (RB selectively)) (VBD inhibited) (NP (NN proliferation) (NN CRC) (NN cell) (NN line)) (ADVP (RB well)) (NP (JJ primary) (NN tumor) (NN cell)))))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 8:C04 41:A11 46:A03.556.124.526.356 55:B01.050.150.900.649.801.400.112.400.400 75:A11.436 122:C14.280.383 183:G04.299.233.750 302:A10.615.550|ES| 2:1 7:1 19:1 36:1 37:1 94:1 113:1 118:1 127:1 245:1 264:1 299:1 344:1 365:1 372:1 428:1 787:1 2489:1 3521:1 3522:1 3523:1

1 	|BT| (S (ADVP (RB Herein)) (, ,) (VP (VBD investigated) (NP (NP (NP (NN effect) (NN alpha-LA) (NN development) (NN rat)) (JJ pre-neoplastic) (NN lesion)) (VP (VBD generated) (NP (NN model) (NN hepatocarcinogenesis) (, ,) (NN similarity) (JJ histopathological) (NN sequence) (JJ human) (JJ hepatocellular) (NN carcinoma) (NN development) (NN cirrhosis)))))) |ET| |BS|8:C04 14:F01.525 25:G02.111.570.080 26:G02.111.570.080 27:G02.111.570.080 30:Z01.058.290.190.800 31:D08.811.520.224.800 104:C04.557.470.200.025.255 245:B01.050.150.900.649.865.635.505.700 246:B01.050.150.900.649.865.635.505.700 357:C06.552.630 662:C23.550.355 1006:D01.268.558.362.500|ES| 2:1 19:1 35:1 36:1 72:1 73:1 75:1 293:1 303:1 304:1 403:1 428:1 849:1 900:1 1131:1 1199:1 3524:1 3525:1 3526:1 3527:1

1 	|BT| (S (ADVP (RB Herein)) (, ,) (VP (VBD investigated) (NP (NP (ADJP (FW vitro) (FW vivo)) (JJ anticancer) (NN effect)) (NP (VBN associated) (NN mechanism) (NN wogonin) (JJ human) (NN breast) (NN cancer))))) |ET| |BS|55:B01.050.150.900.649.801.400.112.400.400|ES| 2:1 18:1 19:1 23:1 36:1 75:1 162:1 169:1 216:1 378:1 403:1 428:1 1880:1 2444:1

1 	|BT| (S (NP (NN Histone) (NN deacetylase) (CD 6) (NN function) (NN tumor) (NN suppressor)) (VP (VBG activating) (NP (NN c-Jun) (JJ NH2-terminal) (JJ kinase-mediated) (NN beclin) (JJ 1-dependent) (JJ autophagic) (NN cell) (NN death) (NN liver) (NN cancer)))) |ET| |BS|206:G05.360.340.024.340.375.249 771:D08.811.913.696.620.682.700.567.374 1007:G04.299.139.399 1008:D08.811.277.087.520|ES| 7:1 18:1 19:1 33:1 94:1 411:1 504:1 700:1 836:1 1686:1 1958:1 2140:1 2708:1 3528:1 3529:1 3530:1 3531:1 3532:1

1 	|BT| (S (NP (NN Honokiol)) (VP (VP (VBZ activates) (NP (JJ AMP-activated) (NN protein) (NN kinase) (NN breast) (NN cancer) (NN cell)) (PP (IN via) (NP (JJ LKB1-dependent) (NN pathway)))) (VP (VBZ inhibits) (NP (NN breast) (NN carcinogenesis))))) |ET| |BS|10:A01.236 33:C04.697.098 41:A11 122:C14.280.383 1009:D08.811.913.696.620.682.700.085|ES| 4:1 18:1 19:1 23:1 94:1 207:1 301:1 383:1 470:1 596:1 615:1 3533:1 3534:1 3535:1

1 	|BT| (S (ADVP (RB However)) (, ,) (NP (JJ molecular) (NN mechanism) (NN progesterone) (NN action) (NN breast) (NN cancer)) (ADVP (RB still)) (VP (VBP remain) (ADJP (JJ elusive)))) |ET| |BS|742:G03.787 1010:D04.808.745.745.654.829|ES| 2:1 18:1 19:1 23:1 161:1 162:1 433:1 776:1 777:1 2013:1 2181:1 3536:1

1 	|BT| (S (NP (NP (JJ Hypoxia-inducible) (NN factor)) (PRN (-LRB- -LRB-) (NP (NNS HIFs)) (-RRB- -RRB-))) (VP (VBP accumulate) (NP (NP (JJ neoplastic) (JJ inflammatory) (NN cell)) (PP (IN within) (NP (NN tumor) (NN microenvironment) (NN impact) (NN progression) (NN variety) (NN disease))) (, ,) (PP (VBG including) (NP (JJ colorectal) (NN cancer)))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 8:C04 16:C23.550.291.656 41:A11 1011:C23.888.852.079 1012:G04.366.500|ES| 2:1 7:1 10:1 14:1 17:1 18:1 19:1 48:1 94:1 185:1 561:1 893:1 952:1 998:1 2122:1 2430:1 3537:1 3538:1 3539:1 3540:1 3541:1

1 	|BT| (NP (NP (NP (JJ Immunohistochemical) (NN analysis) (NN thymidylate) (NN synthase)) (, ,) (NP (NN thymidine) (NN phosphorylase)) (, ,) (NP (NP (NN dihydropyrimidine) (NN dehydrogenase) (JJ rectal) (NN cancer)) (PRN (-LRB- -LRB-) (NP (NN cUICC) (NN II/III)) (-RRB- -RRB-))) (: :)) (NP (NP (NN correlation) (JJ histopathologic) (NN tumor) (NN regression)) (NP (JJ 5-fluorouracil-based) (JJ long-term) (NN neoadjuvant) (NN chemoradiotherapy)))) |ET| |BS|8:C04 59:E02.186.079 333:D01.045 560:D03.383.742.698.875.404 713:D08.811.913.555.500.862 846:F01.393.784 849:G08.686.785.760.769.490.500 869:D08.811.913.400.725.850.500 870:D08.811.682.660.350 1013:E02.186.450|ES| 2:1 7:1 10:1 14:1 18:1 19:1 66:1 104:1 661:1 719:1 1986:1 1989:1 2578:1 2648:1 3002:1 3082:1 3083:1 3084:1 3085:1 3542:1 3543:1 3544:1 3545:1 3546:1 3547:1

1 	|BT| (S (PP (IN In) (NP (NN conclusion))) (, ,) (NP (NN Folbp1) (NN RFC1)) (ADVP (RB genetically)) (VP (NP (VBN modified) (NN mouse) (NN exhibit) (JJ distinct) (NN change) (NN colonocyte) (NN phenotype)) (ADVP (RB therefore)) (SBAR (S (NP (NN utility) (NN model)) (VP (VBP examine) (NP (NP (NN role)) (JJ folate) (NN homeostasis) (NN colon) (NN cancer) (NN development))))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 15:F01.829.316.616 30:Z01.058.290.190.800 31:D08.811.520.224.800 80:G05.695 152:G07.700.345 175:J01.897.280.500.269 224:D03.438.733.631.400|ES| 2:1 18:1 19:1 31:1 35:1 52:1 72:1 113:1 200:1 218:1 236:1 244:1 500:1 587:1 778:1 898:1 960:1 1284:1 2026:1 2194:1 2335:1 3548:1 3549:1 3550:1

1 	|BT| (S (PP (IN In) (NP (NN conclusion))) (, ,) (VP (VBP result) (VP (VBP indicate) (SBAR (S (NP (JJ insulin-independent) (NN liver) (NN tumor) (NN promotion)) (VP (VBD occurred) (NP (JJ diabetic) (NN mouse)))))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 515:C04.588.274.623 637:D06.472.699.587.200.500.625|ES| 2:1 7:1 19:1 52:1 101:1 244:1 553:1 836:1 1284:1 1479:1 2337:1 2964:1 3551:1

1 	|BT| (S (PP (IN In) (NP (NN contrast))) (, ,) (NP (NP (JJ high) (NN level) (NN sPLA2) (NN expression)) (JJ likely) (VBG contributing) (JJ elevated) (NN level) (JJ arachidonic) (NN acid)) (VP (VBD found) (SBAR (S (NP (NP (JJ colorectal) (NN cancer)) (, ,) (NP (NN conjunction) (JJ elevated) (NN expression) (NN cyclooxygenase-2)) (, ,)) (VP (MD could) (NP (DT another) (NN factor) (NN tumor) (NN formation))))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 8:C04 20:G03.495 24:D08.811.600.720.750 491:D27.505.259.500 1014:D10.251.355.255.100.100|ES| 2:1 7:1 17:1 18:1 19:1 37:1 43:1 61:1 115:1 178:1 185:1 244:1 249:1 756:1 908:1 1275:1 1295:1 1328:1 1392:1 3552:1 3553:1 3554:1 3555:1

1 	|BT| (S (PP (IN In) (NP (NN HepG2) (NN cell))) (, ,) (S (S (NP (NN transfection) (NN RARgamma)) (VP (VBD enhanced))) (, ,) (IN whereas) (S (NP (NN downregulation) (NN RARgamma) (NN expression) (NN siRNA) (NN approach)) (VP (VBD impaired)))) (, ,) (NP (NN effect) (NN RA) (VBG inducing) (NN expression) (NN alpha-fetoprotein) (, ,) (NN protein) (NN marker) (NN hepatocarcinogenesis))) |ET| |BS|85:G02.111.087.225 112:D12.776.097.820 117:D13.150.650.700 158:D23.101 217:E05.393.350.810 748:D12.776.124.790.106.092 1015:A11.251.860.180.432|ES| 2:1 4:1 19:1 75:1 94:1 115:1 244:1 351:1 372:1 385:1 534:1 595:1 746:1 900:1 911:1 1864:1 2003:1 2665:1 3481:1 3556:1 3557:1

1 	|BT| (S (PP (IN In) (NP (JJ human) (JJ colorectal) (NN cancer))) (, ,) (NP (JJ arachidonic) (NN acid) (NN eicosanoid) (NN level)) (VP (VBD elevated))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 55:B01.050.150.900.649.801.400.112.400.400 1014:D10.251.355.255.100.100 1016:D10.251.355.255|ES| 2:1 17:1 18:1 19:1 36:1 244:1 249:1 756:1 1275:1 3553:1 3558:1

1 	|BT| (S (PP (IN In) (NP (JJ current) (NN study))) (, ,) (NP (NN serial) (NN microPET) (NN imaging)) (VP (VBD used) (VP (VB evaluate) (NP (NP (JJ iodine-124-labeled) (NN iodo-azomycin-galactoside)) (PRN (-LRB- -LRB-) (NP (-LRB- -LRB-) (CD 124) (-RRB- -RRB-) (NN I-IAZG)) (-RRB- -RRB-))))) (PRN (-LRB- -LRB-) (NP (JJ 4.2-day) (JJ physical) (NN half-life)) (-RRB- -RRB-)) (S (NP (NN hypoxia) (NN imaging) (NN agent)) (NP (CD 17) (NN MCa) (NN breast) (NN tumor) (CD six) (NN FSaII) (NNS fibrosarcomas)) (VP (VBN implanted) (NP (NN mouse))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 30:Z01.058.290.190.800 31:D08.811.520.224.800 225:E05.337 375:Z01.639.100 967:D01.248.497.158.490 1002:C04.588.180 1011:C23.888.852.079 1017:E01.370.350 1018:C04.557.450.565.590.350 1019:A07.231.114.228.550 1020:G01.910.405 1021:E01.370.600 1022:V02.690|ES| 2:1 7:1 10:1 14:1 19:1 23:1 52:1 131:1 175:1 244:1 476:1 728:1 890:1 930:1 1781:1 2474:1 3559:1 3560:1 3561:1 3562:1 3563:1 3564:1 3565:1 3566:1 3567:1 3568:1 3569:1 3570:1 3571:1 3572:1

1 	|BT| (S (PP (IN In) (NP (JJ present) (NN study))) (, ,) (VP (VBD sought) (VP (VB examine) (SBAR (S (NP (NN effectiveness) (NN honokiol) (VBG inhibiting) (NP (NN migration) (NN invasion) (NN breast) (NN cancer) (NN cell))) (VP (VBP elucidate) (S (VP (VBG underlying) (NP (JJ molecular) (NN mechanism)))))))))) |ET| |BS|30:Z01.058.290.190.800 31:D08.811.520.224.800 41:A11 122:C14.280.383|ES| 2:1 18:1 19:1 23:1 94:1 131:1 161:1 162:1 219:1 244:1 435:1 514:1 620:1 880:1 960:1 1307:1 1697:1 3573:1 3574:1

